RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
1.560
-0.100 (-6.02%)
Sep 28, 2026, 3:41 PM EDT - Market open
RenovoRx Revenue
RenovoRx had revenue of $909.00K in the quarter ending June 30, 2026, with 115.40% growth. This brings the company's revenue in the last twelve months to $1.98M, up 198.49% year-over-year. In the year 2025, RenovoRx had annual revenue of $1.12M with 2,511.63% growth.
Revenue (ttm)
$1.98M
Revenue Growth
+198.49%
P/S Ratio
35.06
Revenue / Employee
$116,235
Employees
17
Market Cap
70.40M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.12M | 1.08M | 2,511.63% |
| Dec 31, 2024 | 43.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 68.47M |
| Spero Therapeutics | 47.00M |
| BioStem Technologies | 34.59M |
| Verrica Pharmaceuticals | 30.32M |
| iBio, Inc. | 100.00K |
| Fractyl Health | 3.00K |
RNXT News
- 14 days ago - RenovoRx Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 14 days ago - RenovoRx Slides: Investor presentation - Filings
- 26 days ago - RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th - GlobeNewsWire
- 4 weeks ago - RenovoRx price target raised to $14.50 from $14 at Ascendiant - TheFly
- 4 weeks ago - RenovoRx publishes pharmacokinetic, pharmacodynamic data from TIGeR-PaC trial - TheFly
- 4 weeks ago - RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 5 weeks ago - RenovoRx regains compliance with Nasdaq - TheFly
- 5 weeks ago - RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire